Phase II Panitumumab-IRDye800 in Head & Neck Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Head and Neck Cancer

Interventions

DRUG

Panitumumab-IRDye800

single dose infusion of panitumumab-IRDye800CW

Trial Locations (1)

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER